NCT00806767View on ClinicalTrials.gov

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

May 31, 2011

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
BIOLOGICAL

therapeutic immune globulin

DRUG

busulfan

DRUG

fludarabine phosphate

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Trial Locations (1)

13273

Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille

All Listed Sponsors
lead

Institut Paoli-Calmettes

OTHER

NCT00806767 - Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer | Biotech Hunter | Biotech Hunter